

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016862 A1

(51) International Patent Classification⁷: **C07C 59/64**,
59/68, 59/72, 69/734, 205/44, 205/56, 217/18, 217/76,
229/42

(21) International Application Number:
PCT/JP2004/011952

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003-293590 14 August 2003 (14.08.2003) JP
60/495,734 18 August 2003 (18.08.2003) US

(71) Applicant (for all designated States except US): **ASAHI
KASEI PHARMA CORPORATION** [JP/JP]; 9-1, Kanda
Mitoshiro-cho, Chiyoda-ku, Tokyo 1018481 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHODA, Motoshi**
[JP/JP]; 516-1, Morijima, Fuji-shi, Shizuoka 4160948 (JP).
KURIYAMA, Hiroshi [JP/JP]; 205-8, Obuchi, Fuji-shi,
Shizuoka 4170801 (JP).

(74) Agent: **SIKs & Co.**; 8th Floor, Kyobashi-Nisshoku Bldg.,
8-7, Kyobashi 1-chome, Chuo-ku, Tokyo 1040031 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF**



D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

(57) Abstract: A compound represented by the formula (I)[In the for-
mula, Link represents a saturated or unsaturated straight hydrocarbon
chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) inde-
pendently represent a ring-constituting carbon atom, one of the ring-con-
stituting carbon atoms may be replaced with V, V represents nitrogen
atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl
group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc.,